ImmunisBio Signs First Sales Contract for AI-Based Automated Cell Culture System

ImmunisBio, a company specializing in immune cell therapy, announced on November 12 that it has signed its first sales contract for its independently developed artificial intelligence (AI)-based automated cell culture system, "AutoBator®."

Due to the nature of cell therapy products, which are manufactured by culturing living cells, the "culturing" process is considered a core technology that determines both efficacy and safety. Conventional cell culturing has relied mostly on manual work by highly skilled research personnel. This has posed major obstacles to commercialization, such as inconsistent quality due to operator variability, contamination risks during manual handling, high labor costs, and limited scalability.

ImmunisBio’s "AutoBator," which has now been successfully delivered for the first time, addresses these issues using AI technology. AutoBator utilizes AI-based image analysis to monitor cell density and morphology in real time and automates the entire process.

This enables the stable, large-scale supply of consistently high-quality cell therapy products. It maximizes productivity and dramatically reduces labor costs.

Kang Jeonghwa, CEO of ImmunisBio, stated, "The first sale of AutoBator is more than just a delivery of equipment; it signifies that ImmunisBio’s unique technological capabilities have been validated by the market." She added, "By overcoming the limitations of manual processes, which have been the biggest challenge in cell therapy development, AutoBator will help accelerate the popularization of high-quality cell therapies and expedite our entry into the global market."

ImmunisBio has applied for the technology evaluation, the first step for a technology-special listing on the KOSDAQ market, with Yuanta Securities serving as the lead underwriter.